Rgenix is a privately-held cancer therapeutics company focused on the discovery and development of novel cancer drugs that target key pathways in cancer progression. Using a miRNA based target discovery platform developed by Rgenix scientific co-founders at The Rockefeller University, the company is developing several first-in-class drug candidates to treat cancers of high unmet need. The company brings together distinguished scientific founders and a leadership team with a seasoned Board comprised of experienced drug developers.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
06/15/16	$33,000,000	Series B	Alexandria Real Estate Equities Conegliano Ventures Novo A/S Partnership Fund for New York City Sofinnova Partners	undisclosed
10/09/18	$40,000,000	Series C	Alexandria Venture Investments Lepu Medical Novo Holdings Oceanpine Capital Partnership Fund for New York City Sofinnova Partners WuXi AppTec	undisclosed